vs

Side-by-side financial comparison of Ladder Capital Corp (LADR) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Ladder Capital Corp is the larger business by last-quarter revenue ($22.3M vs $12.5M, roughly 1.8× Avidity Biosciences, Inc.). Ladder Capital Corp runs the higher net margin — 71.0% vs -1398.3%, a 1469.4% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -18.0%). Ladder Capital Corp produced more free cash flow last quarter ($78.7M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -22.5%).

Ladder Capital Corp is a leading commercial real estate finance firm operating primarily across the United States. It originates and manages a diversified portfolio of senior secured commercial mortgage loans, mezzanine debt, commercial mortgage-backed securities, and direct real estate assets, serving property owners, operators and developers across major market segments.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

LADR vs RNA — Head-to-Head

Bigger by revenue
LADR
LADR
1.8× larger
LADR
$22.3M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+452.0% gap
RNA
434.0%
-18.0%
LADR
Higher net margin
LADR
LADR
1469.4% more per $
LADR
71.0%
-1398.3%
RNA
More free cash flow
LADR
LADR
$235.6M more FCF
LADR
$78.7M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-22.5%
LADR

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
LADR
LADR
RNA
RNA
Revenue
$22.3M
$12.5M
Net Profit
$15.9M
$-174.4M
Gross Margin
Operating Margin
69.5%
-1513.5%
Net Margin
71.0%
-1398.3%
Revenue YoY
-18.0%
434.0%
Net Profit YoY
-49.4%
-117.0%
EPS (diluted)
$0.13
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LADR
LADR
RNA
RNA
Q4 25
$22.3M
Q3 25
$27.8M
$12.5M
Q2 25
$21.5M
$3.8M
Q1 25
$20.3M
$1.6M
Q4 24
$27.2M
$3.0M
Q3 24
$38.4M
$2.3M
Q2 24
$34.3M
$2.0M
Q1 24
$37.1M
$3.5M
Net Profit
LADR
LADR
RNA
RNA
Q4 25
$15.9M
Q3 25
$19.2M
$-174.4M
Q2 25
$17.1M
$-157.3M
Q1 25
$11.6M
$-115.8M
Q4 24
$31.3M
$-102.3M
Q3 24
$27.6M
$-80.4M
Q2 24
$32.1M
$-70.8M
Q1 24
$16.4M
$-68.9M
Operating Margin
LADR
LADR
RNA
RNA
Q4 25
69.5%
Q3 25
72.4%
-1513.5%
Q2 25
96.7%
-4448.7%
Q1 25
52.7%
-8360.9%
Q4 24
-4069.6%
Q3 24
74.1%
-4200.9%
Q2 24
90.4%
-4040.4%
Q1 24
49.4%
-2178.6%
Net Margin
LADR
LADR
RNA
RNA
Q4 25
71.0%
Q3 25
69.0%
-1398.3%
Q2 25
79.5%
-4089.3%
Q1 25
56.8%
-7360.0%
Q4 24
115.1%
-3439.5%
Q3 24
71.7%
-3441.7%
Q2 24
93.6%
-3461.8%
Q1 24
44.2%
-1943.4%
EPS (diluted)
LADR
LADR
RNA
RNA
Q4 25
$0.13
Q3 25
$0.15
$-1.27
Q2 25
$0.14
$-1.21
Q1 25
$0.09
$-0.90
Q4 24
$0.25
$-0.80
Q3 24
$0.22
$-0.65
Q2 24
$0.26
$-0.65
Q1 24
$0.13
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LADR
LADR
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$38.0M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.5B
$1.9B
Total Assets
$5.2B
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LADR
LADR
RNA
RNA
Q4 25
$38.0M
Q3 25
$49.4M
$350.2M
Q2 25
$134.9M
$243.9M
Q1 25
$479.8M
$254.2M
Q4 24
$1.3B
$219.9M
Q3 24
$1.6B
$370.2M
Q2 24
$1.2B
$575.8M
Q1 24
$1.2B
$471.4M
Stockholders' Equity
LADR
LADR
RNA
RNA
Q4 25
$1.5B
Q3 25
$1.5B
$1.9B
Q2 25
$1.5B
$1.2B
Q1 25
$1.5B
$1.3B
Q4 24
$1.5B
$1.4B
Q3 24
$1.5B
$1.5B
Q2 24
$1.5B
$1.2B
Q1 24
$1.5B
$830.9M
Total Assets
LADR
LADR
RNA
RNA
Q4 25
$5.2B
Q3 25
$4.7B
$2.1B
Q2 25
$4.5B
$1.4B
Q1 25
$4.5B
$1.5B
Q4 24
$4.8B
$1.6B
Q3 24
$4.8B
$1.6B
Q2 24
$4.8B
$1.3B
Q1 24
$5.3B
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LADR
LADR
RNA
RNA
Operating Cash FlowLast quarter
$87.0M
$-156.2M
Free Cash FlowOCF − Capex
$78.7M
$-156.9M
FCF MarginFCF / Revenue
352.4%
-1257.6%
Capex IntensityCapex / Revenue
37.4%
5.7%
Cash ConversionOCF / Net Profit
5.49×
TTM Free Cash FlowTrailing 4 quarters
$118.3M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LADR
LADR
RNA
RNA
Q4 25
$87.0M
Q3 25
$26.3M
$-156.2M
Q2 25
$44.0M
$-199.7M
Q1 25
$-28.7M
$-124.8M
Q4 24
$133.9M
$-99.9M
Q3 24
$169.0M
$-65.6M
Q2 24
$45.4M
$-65.0M
Q1 24
$-20.4M
$-70.4M
Free Cash Flow
LADR
LADR
RNA
RNA
Q4 25
$78.7M
Q3 25
$25.9M
$-156.9M
Q2 25
$43.4M
$-203.0M
Q1 25
$-29.6M
$-128.6M
Q4 24
$127.4M
$-103.8M
Q3 24
$166.0M
$-67.3M
Q2 24
$44.9M
$-65.5M
Q1 24
$-21.7M
$-71.3M
FCF Margin
LADR
LADR
RNA
RNA
Q4 25
352.4%
Q3 25
93.1%
-1257.6%
Q2 25
201.6%
-5277.1%
Q1 25
-145.6%
-8174.3%
Q4 24
468.2%
-3491.0%
Q3 24
432.1%
-2881.8%
Q2 24
131.0%
-3204.6%
Q1 24
-58.6%
-2012.3%
Capex Intensity
LADR
LADR
RNA
RNA
Q4 25
37.4%
Q3 25
1.7%
5.7%
Q2 25
2.9%
86.9%
Q1 25
4.3%
238.6%
Q4 24
23.9%
131.7%
Q3 24
7.8%
72.9%
Q2 24
1.3%
26.0%
Q1 24
3.7%
25.8%
Cash Conversion
LADR
LADR
RNA
RNA
Q4 25
5.49×
Q3 25
1.37×
Q2 25
2.57×
Q1 25
-2.49×
Q4 24
4.27×
Q3 24
6.13×
Q2 24
1.41×
Q1 24
-1.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons